Claims for Patent: 6,184,256

Summary for Patent: 6,184,256

Title:	Methods and compositions for use in modulating expression of matrix metalloproteinase genes
Abstract:	The present invention relates to methods for identifying and selecting compositions useful in differentially modulating the expression of two or more mammalian genes, particularly matrix metalloproteinase (MMP) genes such as those encoding interstitial collagenase (and other genes comprising an AP1-binding site) and stromelysin-3 (and other genes comprising a retinoic acid response element (RARE)). In addition, the invention relates to methods of treating a mammal (such as a human) suffering from or predisposed to a physical disorder, using pharmaceutical compositions comprising the compositions identified or selected by the above-described methods. The methods of the present invention are useful in treating a variety of physical disorders in mammals including cancers (particularly carcinomas), inflammatory disorders, fibrotic disorders, ocular disorders and osteoporosis.
Inventor(s):	Basset; Paul (Strasbourg, FR), Anglard; Patrick (Strasbourg, FR), Guerin; Eric (Strasbourg, FR)
Assignee:	Institut National de la Sante de la Recherche Medicale (Paris, FR) Centre National de la Recherche Scientifique (Paris, FR) Universite Louis Pasteur (Strasbourg, FR) Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:	09/065,904
Patent Claims:	1. A method of treating a mammal suffering from or predisposed to a physical disorder, comprising administering to said mammal an effective amount of a pharmaceutical composition comprising at least one retinoic acid receptor (RAR) agonist and at least one retinoid X receptor (RXR) agonist, wherein said at least one RAR agonist and said at least one RXR agonist are different compounds, and a pharmaceutically acceptable carrier or excipient therefor, wherein said composition differentially modulates the expression of a first matrix metalloproteinase gene comprising at least one AP1-binding site and a second mammalian matrix metalloproteinase gene comprising at least one retinoic acid response element (RARE). 2. The method of claim 1, wherein said physical disorder is selected from the group consisting of a carcinoma, arthritis, osteoporosis, multiple sclerosis, atherosclerosis, corneal ulceration and diabetic retinopathy. 3. The method of claim 1, wherein said first matrix metalloproteinase gene is an interstitial collagenase gene and said second matrix metalloproteinase gene is a stromelysin-3 gene. 4. The method of claim 1, wherein said RXR agonist is a pan-RXR agonist. 5. The method of claim 1, wherein said RAR agonist is a RAR.alpha. agonist. 6. The method of claim 1, wherein said composition inhibits the expression of said first mammalian matrix metalloproteinase gene. 7. The method of claim 1, wherein said physical disorder is a cancer. 8. The method of claim 4, wherein said pan-RXR agonist is BMS649. 9. The method of claim 5, wherein said RAR.alpha. agonist is BMS753. 10. A method of treating a mammal suffering from or predisposed to a physical disorder, comprising administering to said mammal an effective amount of a pharmaceutical composition comprising at least one RAR agonist and at least one RXR agonist, wherein said at least one RAR agonist and said at least one RXR agonist are different compounds, and a pharmaceutically acceptable carrier or excipient therefor, wherein said composition inhibits the expression of an interstitial collagenase gene in said mammal. 11. The method of claim 10, wherein said RAR agonist is an RAR.alpha. agonist. 12. The method of claim 10, wherein said RXR agonist is a pan-RXR agonist. 13. The method of claim 10, wherein said physical disorder is selected from the group consisting of a carcinoma, arthritis, osteoporosis, multiple sclerosis, atherosclerosis, corneal ulceration and diabetic retinopathy. 14. The method of claim 10, wherein said physical disorder is a cancer. 15. The method of claim 11, wherein said RAR.alpha. agonist is BMS753. 16. The method of claim 12, wherein said pan-RXR agonist is BMS649. 17. A method of treating a human suffering from or predisposed to a physical disorder, comprising administering to said human an effective amount of a pharmaceutical composition comprising at least one RAR agonist and at least one RXR agonist, wherein said at least one RAR agonist and said at least one RXR agonist are different compounds, and a pharmaceutically acceptable carrier or excipient therefor, wherein said composition inhibits the expression of an interstitial collagenase gene in said human. 18. The method of claim 17, wherein said RAR agonist is an RAR.alpha. agonist. 19. The method of claim 17, wherein said RXR agonist is a pan-RXR agonist. 20. The method of claim 17, wherein said physical disorder is selected from the group consisting of a carcinoma, arthritis, osteoporosis, multiple sclerosis, atherosclerosis, corneal ulceration and diabetic retinopathy. 21. The method of claim 17, wherein said physical disorder is a cancer. 22. The method of claim 18, wherein said RAR.alpha. agonist is BMS753. 23. The method of claim 19, wherein said pan-RXR agonist is BMS649.

Details for Patent 6,184,256

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2017-04-24